{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"22.000","floor":"21.000"},"ipodate":{"start":"2019-03-18 00:00:00","end":"2019-03-21 00:00:00"},"minimumcapital":"4444.34","subscribed":"90.83","marketcap":"48.00億","H_marketcap":"28.21億","pe":"--","codesrate":"100.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/06185/LTN20190318020_C.pdf","ipopricing":"22.000","resultdate":"2019-03-27 00:00:00","enddate":"2019-03-21 00:00:00","listeddate":"2019-03-28 00:00:00","issuenumber":"5724.86萬","issuenumberhK":"2289.96萬","issuenumberother":"3434.90萬","grayprice":"29.40","sponsors":"摩根士丹利亞洲有限公司,中信里昂證券資本市場有限公司","raisemoney":"115090.00萬","use":"1、約80%（或920.7百萬港元）將用于我們核心產品以及我們疫苗產品線中其他主要產品的研發及商業化；\n2、約10%（或115.1百萬港元）將用于臨床前在研疫苗的持續研發；\n3、約10%（或115.1百萬港元）將用于營運資金及其他一般企業用途。","shares":200,"leadagent":"摩根士丹利亞洲有限公司,中信里昂證券有限公司,中國國際金融香港證券有限公司,工銀國際證券有限公司,招銀國際融資有限公司","bookrunners":"摩根士丹利亞洲有限公司,中信里昂證券有限公司,中國國際金融香港證券有限公司,工銀國際融資有限公司,招銀國際融資有限公司","coordinator":"摩根士丹利亞洲有限公司,中信里昂證券有限公司,中國國際金融香港證券有限公司","firstDayOpen":"30.50","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"摩根士丹利亞洲有限公司","code":"E06185","name":"康希諾生物－Ｂ","fullname":"康希諾生物股份公司"},"institutioninfo":{"principaloffice":"中國天津市經濟技術開發區西區南大街185號西區生物醫藥園四層401-420","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"Xuefeng YU","secretary":"崔進,趙明璟","telephone":"(86022) 5821 3600","substantialshareholders":"LAV(15.47%),Xuefeng Yu(8.19%),朱濤(8.19%),Dongxu Qiu(7.84%),Helen Huihua Mao(7.49%)","principalactivities":"公司主要從事人用疫苗產品的研發、生產及商品化。","website":"http://www.cansinotech.com"},"managerinfo":[{"managername":"Xuefeng YU","post":"主席、首席執行官兼執行董事","rankno":1},{"managername":"Shou Bai CHAO","post":"首席運營官兼執行董事","rankno":2},{"managername":"朱濤","post":"首席科學官兼執行董事","rankno":3}],"investorinfo":[{"institutionname":"Worldwide Healthcare Trust PLC","shareholding":"8,918,200.0","percentage":15.58,"ReleaseDate":"2019-09-28 00:00:00","relatedparty":"OrbiMed Capital LLC","subsidiary":["OrbiMed Funds","Worldwide Healthcare Trust PLC"],"InverstorType":"基金"},{"institutionname":"津聯卓睿投資有限公司","shareholding":"3,567,200.0","percentage":6.23,"ReleaseDate":"2019-09-28 00:00:00","relatedparty":"天津津聯海河國有企業改革創新發展基金合伙企業(有限合伙)","subsidiary":["津聯卓睿投資有限公司"],"InverstorType":"公司"},{"institutionname":"LAV Amber Limited","shareholding":"3,567,200.0","percentage":6.23,"ReleaseDate":"2019-09-28 00:00:00","relatedparty":"LAV Biosciences Fund V, L.P.","subsidiary":["LAV Prime Limited","LAV Amber Limited"],"InverstorType":"公司"}],"TotalShareholdingPercentage":28.04},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":10}